Skip Nav Destination
Issues
15 August 2017
-
Cover Image
Cover Image
The cover shows a section of a mastectomy from a patient with a primary metaplastic breast carcinoma. This hematoxylin and eosin-stained section shows a component of the tumor with high-grade ductal differentiation. For details, see the article by Avigdor and colleagues on page 4875 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Drug Updates
Molecular Pathways
Special Report
Clinical Trial Brief Report
Author Choice
Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
Ann M. Mohrbacher; Allen S. Yang; Susan Groshen; Shivaani Kummar; Martin E. Gutierrez; Min H. Kang; Denice Tsao-Wei; C. Patrick Reynolds; Edward M. Newman; Barry J. Maurer
Cancer Therapy: Clinical
Phase I Trial of Intratumoral Injection of CCL21 Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration
Jay M. Lee; Mi-Heon Lee; Edward Garon; Jonathan W. Goldman; Ramin Salehi-Rad; Felicita E. Baratelli; Dörthe Schaue; Gerald Wang; Fran Rosen; Jane Yanagawa; Tonya C. Walser; Ying Lin; Stacy J. Park; Sharon Adams; Francesco M. Marincola; Paul C. Tumeh; Fereidoun Abtin; Robert Suh; Karen L. Reckamp; Gina Lee; William D. Wallace; Sarah Lee; Gang Zeng; David A. Elashoff; Sherven Sharma; Steven M. Dubinett
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer
Wendy A. Cooper; Prudence A. Russell; Maya Cherian; Edwina E. Duhig; David Godbolt; Peter J. Jessup; Christine Khoo; Connull Leslie; Annabelle Mahar; David F. Moffat; Vanathi Sivasubramaniam; Celine Faure; Alena Reznichenko; Amanda Grattan; Stephen B. Fox
Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer
Alain R. Thierry; Brice Pastor; Zhi-Qin Jiang; Anastasia D. Katsiampoura; Christine Parseghian; Jonathan M. Loree; Michael J. Overman; Cynthia Sanchez; Safia El Messaoudi; Marc Ychou; Scott Kopetz
Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer
Elahe A. Mostaghel; Eunpi Cho; Ailin Zhang; Mohammad Alyamani; Arja Kaipainen; Sean Green; Brett T. Marck; Nima Sharifi; Jonathan L. Wright; Roman Gulati; Lawrence D. True; Massimo Loda; Alvin M. Matsumoto; Daniel Tamae; Trevor N. Penning; Steven P. Balk; Phillip W. Kantoff; Peter S. Nelson; Mary-Ellen Taplin; R. Bruce Montgomery
Author Choice
PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer
Jian-Ming Xu; Yan Wang; You-Liang Wang; Yan Wang; Tao Liu; Ming Ni; Man-Sheng Li; Li Lin; Fei-Jiao Ge; Chun Gong; Jun-Yan Gu; Ru Jia; He-Fei Wang; Yu-Ling Chen; Rong-Rui Liu; Chuan-Hua Zhao; Zhao-Li Tan; Yang Jin; Yun-Ping Zhu; Shuji Ogino; Zhi-Rong Qian
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Tessa Brabander; Wouter A. van der Zwan; Jaap J.M. Teunissen; Boen L.R. Kam; Richard A. Feelders; Wouter W. de Herder; Casper H.J. van Eijck; Gaston J.H. Franssen; Eric P. Krenning; Dik J. Kwekkeboom
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Susumu Hijioka; Waki Hosoda; Keitaro Matsuo; Makoto Ueno; Masayuki Furukawa; Hideyuki Yoshitomi; Noritoshi Kobayashi; Masafumi Ikeda; Tetsuhide Ito; Shoji Nakamori; Hiroshi Ishii; Yuzo Kodama; Chigusa Morizane; Takuji Okusaka; Hiroaki Yanagimoto; Kenji Notohara; Hiroki Taguchi; Masayuki Kitano; Kei Yane; Hiroyuki Maguchi; Yoshiaki Tsuchiya; Izumi Komoto; Hiroki Tanaka; Akihito Tsuji; Syunpei Hashigo; Yoshiaki Kawaguchi; Tetsuya Mine; Atsushi Kanno; Go Murohisa; Katsuyuki Miyabe; Tadayuki Takagi; Nobutaka Matayoshi; Tsukasa Yoshida; Kazuo Hara; Masayuki Imamura; Junji Furuse; Yasushi Yatabe; Nobumasa Mizuno
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma
Austin G. Duffy; Chi Ma; Susanna V. Ulahannan; Osama E. Rahma; Oxana Makarova-Rusher; Liang Cao; Yunkai Yu; David E. Kleiner; Jane Trepel; Min-Jung Lee; Yusuke Tomita; Seth M. Steinberg; Theo Heller; Baris Turkbey; Peter L. Choyke; Cody J. Peer; William D. Figg; Brad J. Wood; Tim F. Greten
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors
Carolyn D. Britten; Elizabeth Garrett-Mayer; Steven H. Chin; Keisuke Shirai; Besim Ogretmen; Tricia A. Bentz; Alan Brisendine; Kate Anderton; Susan L. Cusack; Lynn W. Maines; Yan Zhuang; Charles D. Smith; Melanie B. Thomas
Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial
Lee Shaashua; Maytal Shabat-Simon; Rita Haldar; Pini Matzner; Oded Zmora; Moshe Shabtai; Eran Sharon; Tanir Allweis; Iris Barshack; Lucile Hayman; Jesusa Arevalo; Jeffrey Ma; Maya Horowitz; Steven Cole; Shamgar Ben-Eliyahu
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Laxmi Silwal-Pandit; Silje Nord; Hedda von der Lippe Gythfeldt; Elen K. Møller; Thomas Fleischer; Einar Rødland; Marit Krohn; Elin Borgen; Øystein Garred; Tone Olsen; Phuong Vu; Helle Skjerven; Anne Fangberget; Marit M. Holmen; Ellen Schlitchting; Elisabeth Wille; Mette Nordberg Stokke; Hans Kristian Moen Vollan; Vessela Kristensen; Anita Langerød; Steinar Lundgren; Erik Wist; Bjørn Naume; Ole Christian Lingjærde; Anne-Lise Børresen-Dale; Olav Engebraaten
Personalized Medicine and Imaging
Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations
Adam A. Friedman; Yun Xia; Lorenzo Trippa; Long Phi Le; Vivien Igras; Dennie T. Frederick; Jennifer A. Wargo; Kenneth K. Tanabe; Donald P. Lawrence; Donna S. Neuberg; Keith T. Flaherty; David E. Fisher
Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
Liana B. Guedes; Fawaz Almutairi; Michael C. Haffner; Gaurav Rajoria; Zach Liu; Szczepan Klimek; Roberto Zoino; Kasra Yousefi; Rajni Sharma; Angelo M. De Marzo; George J. Netto; William B. Isaacs; Ashley E. Ross; Edward M. Schaeffer; Tamara L. Lotan
Author Choice
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Manish Kohli; Yeung Ho; David W. Hillman; Jamie L. Van Etten; Christine Henzler; Rendong Yang; Jamie M. Sperger; Yingming Li; Elizabeth Tseng; Ting Hon; Tyson Clark; Winston Tan; Rachel E. Carlson; Liguo Wang; Hugues Sicotte; Ho Thai; Rafael Jimenez; Haojie Huang; Peter T. Vedell; Bruce W. Eckloff; Jorge F. Quevedo; Henry C. Pitot; Brian A. Costello; Jin Jen; Eric D. Wieben; Kevin A.T. Silverstein; Joshua M. Lang; Liewei Wang; Scott M. Dehm
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine
Hatim Husain; Vladislava O. Melnikova; Karena Kosco; Brian Woodward; Soham More; Sandeep C. Pingle; Elizabeth Weihe; Ben Ho Park; Muneesh Tewari; Mark G. Erlander; Ezra Cohen; Scott M. Lippman; Razelle Kurzrock
In Vivo Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The ϕ-Index
Spyridon Bakas; Hamed Akbari; Jared Pisapia; Maria Martinez-Lage; Martin Rozycki; Saima Rathore; Nadia Dahmane; Donald M. O'Rourke; Christos Davatzikos
Cancer Therapy: Preclinical
Author Choice
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Teeru Bihani; Hitisha K. Patel; Heike Arlt; Nianjun Tao; Hai Jiang; Jeffrey L. Brown; Dinesh M. Purandare; Gary Hattersley; Fiona Garner
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
Ola Rizq; Naoya Mimura; Motohiko Oshima; Atsunori Saraya; Shuhei Koide; Yuko Kato; Kazumasa Aoyama; Yaeko Nakajima-Takagi; Changshan Wang; Tetsuhiro Chiba; Anqi Ma; Jian Jin; Tohru Iseki; Chiaki Nakaseko; Atsushi Iwama
Biology of Human Tumors
Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma
Yuuki Iida; Aaron Ciechanover; Diego M. Marzese; Keisuke Hata; Matias Bustos; Shigeshi Ono; Jinhua Wang; Matthew P. Salomon; Kevin Tran; Stella Lam; Sandy Hsu; Nellie Nelson; Yelena Kravtsova-Ivantsiv; Gordon B. Mills; Michael A. Davies; Dave S.B. Hoon
Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts
Sam L. Ivry; Jeremy M. Sharib; Dana A. Dominguez; Nilotpal Roy; Stacy E. Hatcher; Michele T. Yip-Schneider; C. Max Schmidt; Randall E. Brand; Walter G. Park; Matthias Hebrok; Grace E. Kim; Anthony J. O'Donoghue; Kimberly S. Kirkwood; Charles S. Craik
Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component
Bracha Erlanger Avigdor; Katie Beierl; Christopher D. Gocke; Daniel J. Zabransky; Karen Cravero; Kelly Kyker-Snowman; Berry Button; David Chu; Sarah Croessmann; Rory L. Cochran; Roisin M. Connolly; Ben H. Park; Sarah J. Wheelan; Ashley Cimino-Mathews
Author Choice
Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Vassiliki Saloura; Aiman Fatima; Makda Zewde; Kazuma Kiyotani; Ryan Brisson; Jae-Hyun Park; Yuji Ikeda; Theodore Vougiouklakis; Riyue Bao; Arun Khattri; Tanguy Seiwert; Nicole Cipriani; Mark Lingen; Everett Vokes; Yusuke Nakamura
Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Mariaelena Pierobon; Corinne Ramos; Shukmei Wong; K. Alex Hodge; Jessica Aldrich; Sara Byron; Stephen P. Anthony; Nicholas J. Robert; Donald W. Northfelt; Mohammad Jahanzeb; Linda Vocila; Julia Wulfkuhle; Guido Gambara; Rosa I. Gallagher; Bryant Dunetz; Nicholas Hoke; Ting Dong; David W. Craig; Massimo Cristofanilli; Brian Leyland-Jones; Lance A. Liotta; Joyce A. O'Shaughnessy; John D. Carpten; Emanuel F. Petricoin
Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer
Anna Li; Jin-ji Yang; Xu-chao Zhang; Zhou Zhang; Jian Su; Lan-ying Gou; Yu Bai; Qing Zhou; Zhenfan Yang; Han Han-Zhang; Wen-Zhao Zhong; Shannon Chuai; Qi Zhang; Zhi Xie; Hongfei Gao; Huajun Chen; Zhen Wang; Zheng Wang; Xue-ning Yang; Bin-chao Wang; Bin Gan; Zhi-hong Chen; Ben-yuan Jiang; Si-pei Wu; Si-yang Liu; Chong-rui Xu; Yi-long Wu
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
Joel C. Sunshine; Peter L. Nguyen; Genevieve J. Kaunitz; Tricia R. Cottrell; Sneha Berry; Jessica Esandrio; Haiying Xu; Aleksandra Ogurtsova; Karen B. Bleich; Toby C. Cornish; Evan J. Lipson; Robert A. Anders; Janis M. Taube
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds